article Open AccessTop 1% cited
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Gynecologic Oncology · 2008 · Vol. 109(3) · pp. 323–328
Martee L. Hensley✉(Memorial Sloan Kettering Cancer Center)John A. Blessing(Roswell Park Comprehensive Cancer Center)Koen DeGeest(University of Iowa Hospitals and Clinics)Ovadia Abulafia(SUNY Downstate Health Sciences University)Peter G. Rose(Cleveland Clinic)Howard D. Homesley(Gynecologic Oncology Group)
Uterine Myomas and TreatmentsSarcoma Diagnosis and TreatmentEndometrial and Cervical Cancer TreatmentsMedicineGemcitabineDocetaxelNeutropeniaRegimenInternal medicineToxicityUrologyResponse Evaluation Criteria in Solid TumorsLeiomyosarcoma
MeSH terms
DocetaxelGemcitabineAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFemaleHumansLeiomyosarcomaMiddle AgedNeoplasm Recurrence, LocalUterine NeoplasmsDisease-Free SurvivalTaxoids
Funding
- National Cancer Institute
Citations
362
FWCI
20.70
field-weighted impact
References
43
Percentile
100%
vs. same field & year
Citations per year
Cited by
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Gynecologic Oncology · 2008 · 362 citations
Uterine sarcomas: A review
Gynecologic Oncology · 2009 · 804 citations
References
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Gynecologic Oncology · 2008 · 362 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.